Quality Investor

AdvanSix Inc.

Rank #423Value

ASIX · NYSE · Basic Materials

AdvanSix Inc. (ASIX) — Rank #423 by gross profitability (GP/assets 0.10) · ROE 6.2% · Piotroski F-Score N/A.

As-of 2026-09-28 · CIK 0001673985 · all metrics point-in-time as of the filing date.

About

AdvanSix Inc., integrated chemistry company, engages in the manufacture and sale of polymer resins in the United States and internationally.

Show more

The company offers Nylon 6, a polymer resin, which is a synthetic material used to produce fibers, filaments, engineered plastics, and films. It also provides caprolactam to manufacture polymer resins; ammonium sulfate fertilizers to distributors, farm cooperatives, and retailers; and acetone that are used in the production of adhesives, paints, coatings, solvents, herbicides, and resins. In addition, the company offers intermediate chemicals, including phenol, alpha-methylstyrene, cyclohexanone, oximes, cyclohexanol, and alkyl and specialty amines; and cyclohexanol, sulfuric acid, ammonia, and carbon dioxide, as well as automotive components, water treatment, and pharmaceutical intermediates. It offers its products under the Aegis, Sulf-N, Nadone, Naxol, and EZ-Blox under brand names. The company sells its products directly and through distributors. AdvanSix Inc.

was incorporated in 2016 and is headquartered in Parsippany, New Jersey.

Industry
Chemicals
Sector
Basic Materials
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31

Company Snapshot

P/E and dividend yield are the primary valuation lenses for mature businesses.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

1,410

Industry

Chemicals

Exchange

NYSE

Signal Flags

2 green1 yellow
Revenue growth acceleratingGrowth rate increasing year over year
Sequential beat (rev + EPS)Both revenue and EPS exceeded prior quarter — 1-quarter streak
Disclosure regressionA previously-disclosed line item is no longer reported — worth checking the filing for why

Quality Profile

Profitability

1/1 pass
GP / assets
0.10
Return on equity
6.2%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
1.10
Current ratio
1.28×
Net cash
$7.22M

Cash Flow

2/3 pass
Positive FCF
PASS
Cash-backed earnings
WARN
Accruals healthy
PASS
SBC / revenue
0.4%

Growth

2/2 pass
Revenue growth
0.3%
Piotroski F-Score
N/A
Share dilution
0.3%

Terry Smith quality gate

Passes 0/5 Terry Smith thresholds

3 of 5 thresholds not computable from filed data.

Dividend yield and payout ratio are the primary reads at this stage (trailing P/E — see valuation above).

Profitability

Gross profitability (GP / assets)

0.10

Primary signal (Novy-Marx).

16th pctl of 39 SIC 28 peers

Return on equity

6.2%

Gross margin

10.8%

5th pctl of 39 SIC 28 peers

Revenue growth (YoY)

0.3%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

-7.9%

Revenue CAGR (5Y)

5.6%

Earnings CAGR (3Y)

-34.1%

FCF CAGR (3Y)

-67.3%

Anti-fragile safety

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

1.10

29th pctl of 35 SIC 28 peers (best = lowest)

Current ratio

1.28×

11th pctl of 39 SIC 28 peers

Quick ratio

—

Net cash

$7.22M

Cash & equivalents minus total debt.

Cash-flow health

Free cash flow

$6.42M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF / net income

-0.87

Cash-backing of earnings.

FCF/NI divergence

Unfavorable divergence (yellow flag).

WARN

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

0.4%

Stock-based comp intensity.

Dividend safety

Composite score

1.8 / 5

Weak
Payout ratio
34.8%4/5 Strong
FCF coverage
0.37×0/5 Weak
Dividend growth streak
4 yr2/5 Fair
Balance-sheet health
D/E 1.10 · IC N/A1/5 Weak

Piotroski F-Score

F-Score

N/A

Only 8/9 components determinable.

Lifecycle Phase History

20202025
Capital Return
Hypergrowth
Value